

Filed: September 22, 2017

Filed on behalf of:

**Fisher & Paykel Healthcare Limited**

By: Brenton R. Babcock

Joseph F. Jennings

Matthew S. Bellinger

KNOBBE, MARTENS, OLSON & BEAR, LLP

2040 Main Street, 14th Floor

Irvine, CA 92614

Tel.: (949) 760-0404

Fax: (949) 760-9502

Email: BoxFPH767@knobbe.com

UNITED STATES PATENT AND TRADEMARK OFFICE

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

RESMED LIMITED, RESMED INC., AND RESMED CORP.

Petitioners

v.

FISHER & PAYKEL HEALTHCARE LIMITED,

Patent Owner

---

Case No. IPR2016-01719

U.S. Patent No. 6,398,197

---

**PATENT OWNER'S OBJECTIONS TO EVIDENCE  
SERVED WITH REPLY**

Pursuant to 37 C.F.R. § 42.64(b), Patent Owner Fisher & Paykel Healthcare Limited (“FPH”) objects to the admissibility of evidence served with Petitioners’ Reply to Patent Owner’s Response on September 15, 2017 (Paper No. 17).

| Evidence  | Objections   |
|---|--|
| Ex. 1026<br>Second Declaration of Alexander Virr<br>¶¶ 15-17, 32-34 | 37 C.F.R. § 42.23/77 Fed. Reg. at 48,767 ¶ I: Petitioners improperly rely on portions of Exhibit 1026 in their Reply. As relied on in the Reply, portions of the exhibit include new evidence that cannot properly be raised in Petitioners’ Reply, at least because the portions include new evidence that should have been included in the Petition as part of Petitioners’ alleged <i>prima facie</i> case of unpatentability. For example, the cited portions of the exhibit and corresponding portions of Petitioners’ Reply present new theories and arguments that U.S. Patent No. 5,953,763 to Gouget is allegedly analogous art to FPH’s challenged U.S. Patent No. 6,398,197. <i>See, e.g.</i> , Ex. 1026 ¶¶ 15-17, 32-34; Petitioners’ Reply (Paper No. 17) at 13-15, 23. |

FPH reserves the right: 1) to file a motion to exclude this objectionable exhibit, or portions thereof, and corresponding portions of Petitioners’ Reply (Paper No. 17); 2) to challenge the credibility and/or weight that should be afforded to the exhibit, regardless of whether FPH files a motion to exclude the exhibit; 3) to challenge the sufficiency of the evidence to meet Petitioners’ burden of proof on any issue, regardless of whether FPH has objected to, or files a motion to exclude, the evidence; and 4) to cross examine the declarant regarding his Second Declaration (Ex. 1026).

IPR2016-01719

ResMed v. Fisher & Paykel

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: September 22, 2017

By: /Matthew S. Bellinger/

Brenton R. Babcock (Reg. No. 39,592)

Joseph F. Jennings (Reg. No. 40,664)

Matthew S. Bellinger (Reg. No. 46,547)

Attorneys for Patent Owner

Fisher & Paykel Healthcare Limited

**CERTIFICATE OF SERVICE**

I hereby certify that, pursuant to 37 C.F.R. § 42.6(e)(1) and agreement of the parties, a true and correct copy of **PATENT OWNER'S OBJECTIONS TO EVIDENCE SERVED WITH REPLY** is being served via email on September 22, 2017, to counsel for ResMed Limited, ResMed Inc., and ResMed Corp at the email addresses below:

Michael T. Hawkins  
3200 RBC Plaza  
60 South Sixth Street  
Minneapolis, MN 55402  
IPR36784-0046IP1@fr.com

Stephen R. Schaefer  
Michael J. Kane  
Christopher C. Hoff  
Andrew Dommer  
ptabinbound@fr.com  
FISH & RICHARDSON P.C.  
3200 RBC Plaza, 60 South Sixth Street  
Minneapolis, MN 55402

Dated: September 22, 2017

By: /Matthew S. Bellinger/

Brenton R. Babcock (Reg. No. 39,592)

Joseph F. Jennings (Reg. No. 40,664)

Matthew S. Bellinger (Reg. No. 46,547)

Attorneys for Patent Owner

Fisher & Paykel Healthcare Limited